PLIVA Announces H1 2008 Results

PLIVA d.d.PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. ("Barr"), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with International Financial Reporting Standards (IFRS).

PLIVA reported total revenue of HRK 2,295m for the first half ended 30 June 2008, a decrease of HRK 1,715m compared to revenues of HRK 4,010m in the prior year period, which were positively impacted by significant intragroup product sales to Barr in the first quarter of 2007 and the gain on the sale of the PLIVA US business to Barr in the second quarter of 2007. The first half 2007 revenues also included our Italy and Spain operations, which were both sold in the second half of 2007. Excluding these revenue impacts from the first half of 2007, revenues increased approximately 2% in the first half of 2008 compared to prior year.

For the current period, Earnings Before Interest and Tax (EBIT) was negative HRK 44.4m and Net loss was HRK 102m.

As of 22 July 2008, PLIVA completed its delisting from the London Stock Exchange after completing the termination of its GDR program in June.

About PLIVA d.d.
PLIVA d.d., based in Zagreb, Croatia, serves as the European headquarters for Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operates in more than 30 countries. The Barr Group of companies is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and more than 1,025 products globally outside of the U.S., in the key markets of Croatia, Germany, Poland and Russia. For more information, visit www.barrlabs.com.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pill for skin disease also curbs excessive drinkin…

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promi...

Pfizer's elranatamab receives FDA and EMA filing a…

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) ...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...